Nitrazepam Crescent Pharma (Nitrazepam)

Nitrazepam is a benzodiazepine that acts on the central nervous system to manage several neurological and psychiatric conditions.

• Insomnia: helps initiate and maintain sleep, reducing nighttime awakenings and improving overall sleep quality in patients with primary insomnia.
• Anxiety disorders: alleviates excessive worry and tension, promoting calmness and reducing symptoms in generalized anxiety disorder and related conditions.
• Seizure disorders: provides anticonvulsant activity to control certain focal and generalized seizures, especially those resistant to first‑line therapy.

• Nitrazepam binds to the benzodiazepine site on the γ‑aminobutyric acid‑A (GABA‑A) receptor complex, acting as a positive allosteric modulator. This enhances the affinity of GABA for its receptor, increasing chloride ion influx and hyperpolarizing neuronal membranes, which results in decreased neuronal excitability and produces sedative, anxiolytic, hypnotic and anticonvulsant effects. The potentiation of GABAergic transmission leads to widespread central nervous system depression, accounting for its therapeutic profile.

Nitrazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Drowsiness: persistent sleepiness that may affect daily activities and reduce alertness, especially after the first dose.
• Fatigue: ongoing lack of energy that can interfere with normal functioning and may worsen with higher doses.
• Dizziness: sensation of light‑headedness or vertigo that can increase the risk of falls, particularly in the elderly.
• Impaired coordination: reduced motor control leading to clumsiness or difficulty performing fine‑motor tasks.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can become life‑threatening, requiring immediate medical intervention, especially when combined with other depressants.
• Severe allergic reaction: rash, itching, swelling of face or throat, or anaphylaxis that necessitates urgent treatment.
• Withdrawal seizures: convulsive episodes that may occur if the medication is stopped abruptly after prolonged use, highlighting the need for tapering.

When prescribing Nitrazepam, clinicians should consider several safety measures to minimize risks.

• Abrupt discontinuation: avoid sudden stop to prevent withdrawal seizures and rebound anxiety.
• Elderly patients: use lower doses and monitor for excessive sedation or falls.
• Concomitant CNS depressants: avoid or limit alcohol, opioids, and other sedatives to reduce respiratory depression risk.
• Liver impairment: adjust dosing and monitor hepatic function as the drug is metabolized hepatically.
• Pregnancy: classified Category D; use only if benefits outweigh potential fetal risks.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Nitrazepam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Opioids: combined use may cause profound respiratory depression and profound sedation.
• Barbiturates: additive CNS depression can lead to severe impairment or coma.
• Antifungal azoles (e.g., ketoconazole): may increase nitrazepam plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): may enhance sedative effects and increase risk of serotonin syndrome.
• Antihistamines: can potentiate drowsiness and impair cognition.